Advertisement

Metabolism of Drugs by Activated Leukocytes: Implications for Drug-Induced Lupus and Other Drug Hypersensitivity Reactions

  • Jack Uetrecht
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 283)

Abstract

Adverse drug reactions represent a serious medical problem. Idiosyncratic reactions are especially disconcerting because of their unpredictable nature which makes them difficult to prevent, and because they are associated with a relatively high mortality rate. General agreement on the definition of an idiosyncratic reaction is lacking, but the term will be used to mean a reaction that does not occur in most patients given the drug even at a high dose, and one that does not represent a manifestation of the known pharmacological effects of a drug. The mechanism of idiosyncratic reactions is unknown, and several different mechanisms may be involved. The study of idiosyncratic reactions is very difficult because they do not occur in most patients, and by extension, they do not occur in most animals even at a very high dose. Thus, there are very few animal models of idiosyncratic reactions which would permit careful investigation of their mechanism. It is probable that if enough different types of animals were tried, an animal model could be developed, but it might take many thousands of different species before one was found that would have a reaction similar to the rare individual human that has a reaction. It should be noted that, although a specific adverse reaction to a specific drug may be rare, there are enough different drugs being given to enough different individuals that idiosyncratic reactions are very common.

Keywords

Antinuclear Antibody Covalent Binding Histone Protein Reactive Metabolite Thyroid Peroxidase 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Alarcon-Segovia, D., Fishbein, E., Reyes, P.A., Dies, H. and Shwadsky, S. (1972). Antinuclear antibodies in patients on anticonvulsant therapy. Clin. Exp. Immunol. 12, 39–47.PubMedGoogle Scholar
  2. Amrhein, J.A., Kenny, F.M. and Ross, D. (1970). Granulocytopenia, lupus-like syndrome, and other complications of propylthiouracil therapy. J. Pediat. 76, 54–63.CrossRefPubMedGoogle Scholar
  3. Aucoin, D.P., Peterson, M.E., and Hurvitz, A.I., (1985). Propylthiouracil-induced immune-mediated disease in the cat. J. Pharmacol. Exp. Ther. 234, 13–18.PubMedGoogle Scholar
  4. Aucoin, D.P., Rubin, R.L., and Peterson, M.E. (1988). Dose-dependent induction of anti-native DNA antibodies in cats by propylthiouracil. Arthritis Rheum. 31, 688–692.CrossRefPubMedGoogle Scholar
  5. Engler, H., Taurog, A. and Nakashima, T. (1982). Mechanism of inactivation of thyroid peroxidase by thioureylene drugs. Biochem. Pharmacol. 31, 3801–3806.CrossRefPubMedGoogle Scholar
  6. Fritzler, M.J. and Tan, E.M. (1978). Antibodies to histones in drug-induced and idiopathic lupus erythematosus. J. Clin. Invest. 62, 560–567.CrossRefPubMedGoogle Scholar
  7. Gorsulowsky, D.C., Bank, P.W., Goldberg, A.D., Lee, T.G., Heinzerling, R.H. and Burnham, T.K. (1985). Antinuclear antibodies as indicators for the procainamide-induced systemic lupus erythematosus-like syndrome and its clinical presentations. J. Am. Acad. Dermatol. 12, 245–253.CrossRefPubMedGoogle Scholar
  8. Gruciute,L. and Tomatis, L. (1980). Carcinogenicity of dapsone in mice and rats. Int. J. Cancer 25, 123–129.CrossRefGoogle Scholar
  9. Gupta, A., Waldhauser, L., Reider, M. (1988). Drug-induced hypothyroidism: the thyroid as a target organ in hypersensitivity reactions. Soc. Ped. Res. 23, 277A.Google Scholar
  10. Hofstra, A. and Uetrecht, J. (1988). Oxidation of hydralazine by monocytes as a mechanism of hydralazine-induced lupus. Pharmacologist 30. A99.Google Scholar
  11. Klebanoff, S.J. and Clark, r.a. (1978). The Neutrophil: Function and Clinical Disorders, Elsevier/North-Holland Inc. Amsterdam.Google Scholar
  12. Lee, E., Hirouchi, M., Hosokawa, M., Sayo, H., Kohno, M. and Kariya, K. (1988a). Inactivation of peroxidases of rat bone marrow by repeated administration of propylthiouracil is accompanied by a change in the heme structure. Biochem. Pharmacol. 37, 2151–2153.CrossRefPubMedGoogle Scholar
  13. Lee, E., Miki, Y., Hosokawa, M., Sayo, H. and Kariya, K. (1988b). Oxidative metabolism of propylthiouracil by peroxidases from rat bone marrow. Xenobiotica 18, 1135–1142.CrossRefPubMedGoogle Scholar
  14. Lehrer, R.I., Ganz, T., Selsted, M.E., Babior, B.M. and Curnutte, J.T. (1988). Neutrophils and host defense. Ann. Intern. Med. 109, 127–142.PubMedGoogle Scholar
  15. Li, A. and Uetrecht, J. (1988). Metabolism of isoniazid by activated neutrophils. Pharmacologist 30, A99.Google Scholar
  16. Moloney, S.J. and Prough, R.A. (1983). Biochemical toxicology of hydrazines. In Reviews in Biochemical Toxicology. ( Hodgson, E., Bend, J.R., Philpot, R.M., ed), 313–348. Elsevier, New York.Google Scholar
  17. Murao, S., Stevens, F.J., Ito, A. and Huberman, E. (1988). Myeloperoxidase: a myeloid cell nuclear antigen with DNA-binding properties. Proc. Natl. Acad. Sci. USA 85, 1232–1236.CrossRefPubMedGoogle Scholar
  18. Park, B.K., Coleman, J.W. and Kitteringham, N.R. (1987). Drug disposition and drug hypersensitivity. Biochem. Pharmacol. 36, 581–590.CrossRefPubMedGoogle Scholar
  19. Parker, C.W. (1980). Drug allergy. In Clinical Immunology ( Parker C.W. ed), 1219–1260. W.B. Saunders, Philadelphia.Google Scholar
  20. Pohl, L.R., Satoh, H., Christ, D.D. and Kenna, J.G. (1988). the immunologic and metabolic basis of drug hypersensitivities. Ann. Rev. Pharmacol. 28, 367–387.CrossRefGoogle Scholar
  21. Radomski, J.L. (1979). the primary aromatic amines: their biological properties and structur-activity relationships. Ann. Rev. Pharmacol. Toxicol. 19, 129–157.CrossRefGoogle Scholar
  22. Reidenberg, M.M. (1983). Aromatic amines and the pathogenesis of lupus erythematosus. Am. J. Med. 75, 1037–1042.CrossRefPubMedGoogle Scholar
  23. Rubin, R.L., Uetrecht, J.P. and Jones, J.E. (1987). Cytotoxicity of oxidative metabolites of procainamide. J. Pharmacol. Exp. Ther. 242, 833–841.PubMedGoogle Scholar
  24. Schwartz, R.S. and Stoller, B.D. (1985). Origins of anti-DNA autoantibodies. J. Clin. Invest. 75, 321–327.CrossRefPubMedGoogle Scholar
  25. Stendahl, O., Molin, L. and Dahlgren, C. (1978). the inhibition of polymorphonuclear keukocyte cytotoxicity by dapsone: a possible mechanism in the treatment of dermatitis herpetiformis. J. Clin. Invest. 62, 214–220.CrossRefPubMedGoogle Scholar
  26. Takayama, S., Aihara, K., Onodera, T. and Akimoto, T. (1986). Antithyroid effects of propylthiouracil and sulfamonomethoxine in rats and monkeys. Toxicol. Appt. Pharmacol. 82, 191–199.CrossRefGoogle Scholar
  27. Takuwa, N., Kojima, I. and Ogata, E. (1981). Lupus-like syndrome–a rare complication in thionamide treatment for Graves’ disease. Endocrinol. Japan. 28, 663–667.CrossRefGoogle Scholar
  28. Timbrell, J.A., Facchini, V., Harland, S.J. and Mansilla-Tinoco, R. (1984). Hydralazine-induced lupus: is there a toxic pathway? Eur. J. Clin. Pharmacol. 27, 555–559.CrossRefPubMedGoogle Scholar
  29. Uetrecht, J. (1989). Mechanism of hypersensitivity reactions: proposed involvement of reactive metabolites generated by activated leukocytes. Trends Pharmacol. Sci. 10, 463–467.CrossRefPubMedGoogle Scholar
  30. Uetrecht, J. and Zahid, N. (1988a). N-Chlorination of phenytoin by myeloperoxidase to a reactive metabolite. Chem. Res. Toxicol. 1, 148–151.CrossRefPubMedGoogle Scholar
  31. Uetrecht, J. and Zahid, N. (1988b). Procainamide (PA) is N-chlorinated by myeloperoxidase (MPO)-implications for toxicity. Pharmacologist 30, A98.Google Scholar
  32. Uetrecht, J., Zahid, N. and Rubin, R. (1988a). Metabolism of procainamide to a hydroxylamine by human neutrophils and mononuclear leukocytes. Chem. Res. Toxicol. 1, 74–78.CrossRefPubMedGoogle Scholar
  33. Uetrecht, J., Zahid, N. Shear, N.H. and Biggar, W.D. (1988b). Metabolism of dapsone to a hydroxylamine by human neutophils and mononuclear cells. J. Pharmacol. Exp. Ther. 245, 274–279.PubMedGoogle Scholar
  34. Uetrecht, J.P. (1985). reactivity and possible significance of hydroxylamine and nitroso metabolites of procainamide. J. Pharmacol. Exp. Ther. 232, 420–425.PubMedGoogle Scholar
  35. Uetrecht, J.P. (1988). Mechanism of drug-induced lupus. Chem. Res. Toxicol. 1, 133–143.CrossRefPubMedGoogle Scholar
  36. Uetrecht, J.P. (1990). Drug metabolism by leukocytes, its role in drug-induced lupus and other idiosyncratic drug reactions. CRC Crit. Rev. Tox, in press.Google Scholar
  37. Uetrecht, J.P., Shear, N. and Biggar, W. (1986). Dapsone is metabolised by human neutrophils to a hydroxylamine. Pharmacologist 28, 239.Google Scholar
  38. Uetrecht, J.P. and Woosley, R.L. (1981). Acetylator phenotype and lupus erythematosus. Clin. Pharmacokin. 6, 118–134.CrossRefGoogle Scholar
  39. Uetrecht, J.P., Woosley, r.L., Freeman, r.W., Sweetman, B.J. and Oates, J.A. (1981). Metabolism of procainamide in the perfused rat liver. Drug Metab. Disp. 9, 183–187.Google Scholar
  40. Unanue, E.R. and allen, P.M. (1987). the basis for the immunoregulatory role of macrophages and other accessory cells. Science 236, 551–557.CrossRefPubMedGoogle Scholar
  41. Waldhauser, L. and Uetrecht, J. (1988). Propylthiouracil (PTU) is metabolized by activated neutrophils-implications for agranulocytosis. FASEB J. 2, A1134.Google Scholar
  42. Wallace, D.J. and Dubois, E.L. (1987). Dubois’ Lupus Erythematosus (3rd ed.), Lea and Febiger, Philadelphia.Google Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Jack Uetrecht
    • 1
  1. 1.Faculties of Pharmacy and Medicine University of Toronto and Sunnybrook Medical Centre Centre for Drug Safety ResearchUniversity of TorontoTorontoCanada

Personalised recommendations